Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Solta Medical, Ltd. (“Solta Medical” or the “Company”) (Nasdaq:SLTM) relating to the proposed acquisition of the company by Valeant Pharmaceuticals International.
Click here to learn more about the investigation http://brodsky-smith.com/687-sltm-solta-medical-inc.html, or call 877-534-2590. There is no cost or obligation to you.
Under the terms of the transaction, Solta Medical shareholders will receive only $2.92 in cash for each share of Solta Medical stock they own. The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Solta Medical for not acting in the Company’s shareholders’ best interests in connection with the sale process. The transaction may undervalue the Company and will result in a loss or no real gain for many long term Solta Medical shareholders. Solta Medical stock traded above the sale price at $3.48 per share on July 27, 2012 and traded at $2.75 per share as recently as July 29, 2013. In addition, an analyst has set a $4.00 per share price target on Solta Medical shares.
If you own shares of Solta Medical common stock and wish to discuss the legal ramifications of the proposed transaction, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at firstname.lastname@example.org, by visiting http://brodsky-smith.com/687-sltm-solta-medical-inc.html, or calling toll free 877-LEGAL-90.Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and case action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts